Guo Yongdong, Dong Xiaoping, Jin Jing, He Yutong
Cancer Institute, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Front Cell Dev Biol. 2021 Sep 28;9:663001. doi: 10.3389/fcell.2021.663001. eCollection 2021.
Increasing evidence supports that proteasome activator subunit (PSME) genes play an indispensable role in multiple tumors. The diverse expression patterns, prognostic value, underlying mechanism, and the role in the immunotherapy of genes in gastric cancer (GC) have yet to be fully elucidated. We systematically demonstrated the functions of these genes in GC using various large databases, unbiased approaches, and experimental validation. We found that the median expression levels of all genes were significantly higher in GC tissues than in normal tissues. Our findings showed that up-regulated and expression significantly correlated with favorable overall survival, post-progression survival, and first progression survival in GC patients. The expression of and was positively correlated with the infiltration of most immune cells and the activation of anti-cancer immunity cycle steps. Moreover, GC patients with high and expression have higher immunophenoscore and tumor mutational burden. In addition, a receiver operating characteristic analysis suggested that and had high diagnostic performance for distinguishing GC patients from healthy individuals. Moreover, our further analysis indicated that genes exert an essential role in GC, and the present study indicated that and may be potential prognostic markers for enhancing survival and prognostic accuracy in GC patients and may even act as potential biomarkers for GC patients indicating a response to immunotherapy. may serve as an oncogene in tumorigenesis and may be a promising therapeutic target for GC. PSME4 had excellent diagnostic performance and could serve as a good diagnostic indicator for GC.
越来越多的证据支持蛋白酶体激活亚基(PSME)基因在多种肿瘤中发挥不可或缺的作用。胃癌(GC)中这些基因的不同表达模式、预后价值、潜在机制及其在免疫治疗中的作用尚未完全阐明。我们使用各种大型数据库、无偏倚方法和实验验证系统地证明了这些基因在GC中的功能。我们发现,所有这些基因在GC组织中的中位表达水平显著高于正常组织。我们的研究结果表明,上调的[具体基因1]和[具体基因2]表达与GC患者良好的总生存期、进展后生存期和首次进展生存期显著相关。[具体基因1]和[具体基因2]的表达与大多数免疫细胞的浸润以及抗癌免疫循环步骤的激活呈正相关。此外,[具体基因1]和[具体基因2]表达高的GC患者具有更高的免疫表型评分和肿瘤突变负担。此外,受试者工作特征分析表明,[具体基因1]和[具体基因2]在区分GC患者和健康个体方面具有较高的诊断性能。此外,我们的进一步分析表明,这些基因在GC中发挥着重要作用,本研究表明,[具体基因1]和[具体基因2]可能是提高GC患者生存率和预后准确性的潜在预后标志物,甚至可能作为GC患者对免疫治疗有反应的潜在生物标志物。[具体基因3]可能在肿瘤发生中作为癌基因,可能是GC的一个有前景的治疗靶点。PSME4具有出色的诊断性能,可作为GC的良好诊断指标。